Anticancer therapeutics : (Record no. 643421)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08606cam a22007938i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250919132323.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 190918s2017 nju ob 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
| LC control number | 2017-025861 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118696217 |
| Qualifying information | (pdf) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118696212 |
| Qualifying information | (pdf) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118696194 |
| Qualifying information | (epub) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118696190 |
| Qualifying information | (epub) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118696200 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118696204 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118622124 |
| Qualifying information | (cloth) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118622117 |
| Qualifying information | (pbk.) |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | CHNEW |
| System control number | 000979892 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | CHVBK |
| System control number | 507395417 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | GBVCP |
| System control number | 1015064957 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)988580997 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)ocn988580997 |
| 037 ## - SOURCE OF ACQUISITION | |
| Stock number | 9781118696200 |
| Source of stock number/acquisition | Wiley |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] | |
| Level of rules in bibliographic description | 201911041146 |
| Level of effort used to assign nonsubject heading access points | ros |
| y | 09-18-2019 |
| z | hafiz |
| w | UKM UBCM Wiley MARC (363 titles).mrc |
| x | 41 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | DLC |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | DLC |
| Modifying agency | OCLCO |
| -- | OCLCQ |
| -- | YDX |
| -- | IDEBK |
| -- | OCLCO |
| -- | NLE |
| -- | EBLCP |
| -- | OCLCO |
| -- | UIU |
| -- | DG1 |
| -- | OCLCA |
| -- | OCLCF |
| -- | UAB |
| -- | OCLCO |
| -- | UPM |
| -- | CHVBK |
| -- | RECBK |
| -- | OCLCO |
| -- | OCLCQ |
| -- | OCLCA |
| -- | CASUM |
| -- | OCLCO |
| -- | OCLCQ |
| -- | AU@ |
| -- | WYU |
| -- | OCLCQ |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | pcc |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 050 10 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC270.8 |
| 060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | QZ 267 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99/4061 |
| Edition information | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Todd, Adam, |
| Dates associated with a name | 1982- |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Anticancer therapeutics : |
| Remainder of title | from drug discovery to clinical applications / |
| Statement of responsibility, etc. | Dr. Adam A. Todd, Professor Paul W. Groundwater, Dr. Jason Gill. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | First edition. |
| 263 ## - PROJECTED PUBLICATION DATE | |
| Projected publication date | 1712 |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hoboken, NJ : |
| Name of producer, publisher, distributor, manufacturer | Wiley, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2017. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright Page -- Contents -- Preface -- Section 1 Introduction -- Chapter 1.1 The Global Burden of Cancer -- References -- Chapter 1.2 Cancer Staging and Classification -- 1.2.1 Benign Tumour (or neoplasm) -- 1.2.2 Malignant Tumour (or cancer) -- 1.2.3 Tumour Nomenclature and Classification -- 1.2.4 Cellular Differentiation and Tumour Grade -- 1.2.5 Tumour Invasion and Metastasis -- 1.2.6 Clinical Staging of Cancer -- References -- Chapter 1.3 Cellular and Molecular Basis of Cancer -- 1.3.1 Oncogenes -- 1.3.2 Tumour Suppressor Genes -- 1.3.3 Role of Epigenetics and Gene Promoter Regulation in Tumourigenesis -- 1.3.4 Multistage Tumourigenesis -- 1.3.5 Oncogene Addiction -- 1.3.6 Hallmarks of Cancer -- 1.3.7 Principles of Cancer Treatment -- References -- Section 2 The Anticancer Agents -- Chapter 2.1 Agents Which Act Directly on DNA -- 2.1.1 Nitrogen Mustards and Nitrosoureas -- References -- 2.1.2 Temozolomide -- References -- 2.1.3 Platinum-containing agents -- References -- 2.1.4 Gemcitabine -- References -- 2.1.5 Camptothecin and Its Analogues -- References -- 2.1.6 Podophyllotoxins -- References -- 2.1.7 Anthracyclines [1] -- References -- 2.1.8 Epigenetic Targeting Agents [1] -- References -- Chapter 2.2 Antimetabolites -- 2.2.1 Cytarabine -- References -- 2.2.2 Methotrexate -- References -- 2.2.3 5-Fluorouracil -- References -- 2.2.4 6-Mercaptopurine -- References -- Chapter 2.3 Antimicrotubule agents -- 2.3.1 Taxanes -- References -- 2.3.2 Vinca Alkaloids -- References -- Chapter 2.4 Anti-hormonal agents -- 2.4.1 Bicalutamide -- References -- 2.4.2 Tamoxifen -- References -- 2.4.3 Anastrozole [1] -- References -- Chapter 2.5 Kinase Inhibitors -- 2.5.1 Discovery -- 2.5.2 Synthesis -- 2.5.3 Mode of Action -- 2.5.4 Mechanism of Resistance [32] -- 2.5.5 Adverse Drug Reactions -- References -- Section 3 The Cancers. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 3.1 Breast Cancer -- 3.1.1 Epidemiology -- 3.1.2 Presentation -- 3.1.3 Diagnosis -- 3.1.4 Staging -- 3.1.5 Treatments -- References -- Chapter 3.2 Colorectal cancer -- 3.2.1 Epidemiology -- 3.2.2 Presentation -- 3.2.3 Diagnosis -- 3.2.4 Staging -- 3.2.5 Treatments -- References -- Chapter 3.3 Leukaemia -- 3.3.1 Epidemiology -- 3.3.2 Presentation -- 3.3.3 Diagnosis -- 3.3.4 Staging -- 3.3.5 Treatments -- References -- Chapter 3.4 Lung cancer -- 3.4.1 Epidemiology -- 3.4.2 Presentation -- 3.4.3 Diagnosis -- 3.4.4 Staging -- 3.4.5 Treatments -- References -- Chapter 3.5 Oesophageal Cancer -- 3.5.1 Epidemiology -- 3.5.2 Presentation -- 3.5.3 Diagnosis -- 3.5.4 Staging -- 3.5.5 Treatments -- References -- Chapter 3.6 Ovarian cancer -- Key points -- 3.6.1 Epidemiology -- 3.6.2 Presentation -- 3.6.3 Diagnosis -- 3.6.4 Staging -- 3.6.5 Treatments -- References -- Chapter 3.7 Pancreatic Cancer -- 3.7.1 Epidemiology -- 3.7.2 Presentation -- 3.7.3 Diagnosis -- 3.7.4 Staging -- 3.7.5 Treatments -- References -- Chapter 3.8 Prostate Cancer -- 3.8.1 Epidemiology -- 3.8.2 Presentation -- 3.8.3 Diagnosis -- 3.8.4 Staging -- 3.8.5 Treatments -- References -- Chapter 3.9 Skin Cancers -- 3.9.1 Epidemiology -- 3.9.2 Presentation -- 3.9.3 Diagnosis -- 3.9.4 Staging -- 3.9.5 Treatments -- References -- Chapter 3.10 Testicular cancer -- 3.10.1 Epidemiology -- 3.10.2 Presentation -- 3.10.3 Diagnosis -- 3.10.4 Staging -- 3.10.5 Treatments -- References -- Index -- EULA. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | An integrated presentation of the basic science and clinical applications of anticancer agents Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications. After heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year. Anticancer Therapeutics is divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents-their discovery, synthesis, mode of action, mechanisms of resistance, and adverse reactions. Section 3 focuses on specific cancers, explaining how and why the various agents discussed in Section 2 are used, both individually and in combination, to treat different cancers.-Integrates aspects of basic science, including chemistry and pharmacology and clinical medicine in relation to cancer therapeutics -Written by an author team comprising specialists in medicinal chemistry, pharmacology, and oncology -Features full-color images throughout illustrating how drugs bind to cellular targets and exert their pharmacological effect -Divided into three sections, covering the etiology and cellular and molecular basis of cancer, anticancer agents, and drug applications for different cancers. Providing the reader with an integrated understanding of all aspects of the science of anticancer agents, this is an ideal textbook for undergraduates studying medicine, nursing, medicinal chemistry, pharmacy, pharmacology and other allied heath / life sciences. It is also a valuable bench reference for pharmacists, medics, and pharmaceutical researchers working in both academia and industry. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Print version record and CIP data provided by publisher; resource not viewed. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents |
| General subdivision | Development. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents |
| General subdivision | Design. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | therapeutic use. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasms |
| General subdivision | Drug therapy. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasms |
| General subdivision | physiopathology. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Discovery. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | SCIENCE |
| General subdivision | Chemistry |
| -- | Industrial & Technical. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents |
| General subdivision | Design. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00810598 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents |
| General subdivision | Development. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00810599 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents |
| General subdivision | Therapeutic use. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00810609 |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Groundwater, Paul W., |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gill, Jason H., |
| Dates associated with a name | 1973- |
| Relator term | author. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Wiley e-books |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Todd, Adam A., 1982- |
| Title | Anticancer therapeutics. |
| Edition | First edition. |
| Place, publisher, and date of publication | Hoboken, NJ : Wiley, 2017 |
| International Standard Book Number | 9781118622124 |
| Record control number | (DLC) 2017024305 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://eresourcesptsl.ukm.remotexs.co/user/login?url=https://onlinelibrary.wiley.com.eresourcesptsl.ukm.remotexs.co/doi/book/10.1002/9781118696194">https://eresourcesptsl.ukm.remotexs.co/user/login?url=https://onlinelibrary.wiley.com.eresourcesptsl.ukm.remotexs.co/doi/book/10.1002/9781118696194</a> |
| Public note | Wiley Online Library |
| 907 ## - LOCAL DATA ELEMENT G, LDG (RLIN) | |
| a | .b16755340 |
| b | 2022-11-04 |
| c | 2019-11-12 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
| 914 ## - VTLS Number | |
| VTLS Number | vtls003651191 |
| 998 ## - LOCAL CONTROL INFORMATION (RLIN) | |
| Library | |
| Operator's initials, OID (RLIN) | 2019-05-09 |
| Cataloger's initials, CIN (RLIN) | m |
| Material Type (Sierra) | E-Book |
| Language | English |
| Country | |
| -- | 0 |
| -- | .b16755340 |
No items available.